0 WU

World Journal of **Gastrointestinal** Oncology

Submit a Manuscript: https://www.f6publishing.com

World J Gastrointest Oncol 2025 April 15; 17(4): 102258

DOI: 10.4251/wjgo.v17.i4.102258

ISSN 1948-5204 (online)

CASE REPORT

Quadruple therapy with immunotherapy and chemotherapy as firstline conversion treatment for unresectable advanced gastric adenocarcinoma: A case report

Xiao-Yu Du, Ren-Jie Xia, Li-Wen Shen, Jian-Guo Ma, Wei-Qing Yao, Wei Xu, Zhi-Peng Lin, Liang-Bin Ma, Guo-Qiang Niu, Rui-Fang Fan, Shu-Mei Xu, Long Yan

Specialty type: Oncology	Xiao-Yu Du, Ren-Jie Xia, Jian-Guo Ma, Wei-Qing Yao, Wei Xu, Zhi-Peng Lin, Liang-Bin Ma, Guo- Qiang Niu, Rui-Fang Fan, Shu-Mei Xu, Long Yan, Department of Hepatobiliary Surgery and
Provenance and peer review:	General Surgery, The 940 th Hospital of Joint Logistic Support Force of Chinese People's
Unsolicited article; Externally peer reviewed.	Liberation Army, Lanzhou 730050, Gansu Province, China
	Xiao-Yu Du, Ren-Jie Xia, Wei-Qing Yao, Department of Medicine, Northwest Minzu University,
Peer-review model: Single blind	Lanzhou 730050, Gansu Province, China
Peer-review report's classification	Li-Wen Shen, Department of Medical Support Center, The 940th Hospital of Joint Logistic
Scientific Quality: Grade A, Grade	Support Force of Chinese People's Liberation Army, Lanzhou 730050, Gansu Province, China
A, Grade C	Jian-Guo Ma. First School of Clinical Medicine, Gansu University of Chinese Medicine
Novelty: Grade A, Grade A, Grade A	Lanzhou 730030, Gansu Province, China
Creativity or Innovation: Grade A,	Co-first authors: Xiao-Yu Du and Ren-Jie Xia.
Grade B, Grade B	
Scientific Significance: Grade A,	Co-corresponding authors: Shu-Mei Xu and Long Yan.
Grade A, Grade B	Corresponding author: Long Yan, MD, Associate Chief Physician, Department of Hepatobiliary
P-Reviewer: Gugulothu D; Jiang YC	Surgery and General Surgery, The 940 th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, No. 333 Nanbinhe Middle Road, Qilihe District, Lanzhou 730050, Gansu Province, China. lzzy940@163.com
Received: October 13, 2024	
Revised: January 20, 2025	
Accepted: February 24, 2025	Abstract
Published online: April 15, 2025	BACKGROUND
Processing time: 163 Days and 8.4	The treatment of gastric cancer remains highly challenging, particularly in cases of
Hours	unresectable locally advanced or metastatic disease. Although chemotherapy and
	immunotherapy have shown some efficacy in such patients, significant limitations persist in extending survival and enhancing safety. To address these challenges, we designed an innovative first-line quadruple conversion therapy regimen that integrates a programmed cell death protein 1 (PD-1) inhibitor with chemotherapy,

CASE SUMMARY

We report the case of a 55-year-old male who was diagnosed with unresectable

and we successfully implemented this therapy regimen in the treatment of a

patient with unresectable locally advanced gastric adenocarcinoma.



Du XY et al. Quadruple therapy with PD-1 inhibitor and chemotherapy

locally advanced gastric adenocarcinoma and presented with intermittent epigastric pain and multiple lymph node metastases in the abdominal cavity, with the metastasis being notably large in size. The tumor tissue was negative for human epidermal growth factor receptor 2 by immunohistochemistry. Considering the patient's status, the multidisciplinary team decided to administer sintilimab in combination with albumin-bound paclitaxel (nab-paclitaxel), S-1, and oxaliplatin as a quadruple drug conversion therapy. After 4 cycles of conversion therapy, the patient's epigastric pain was significantly alleviated, his stool color normalized, the volume of the primary tumor and lymph node metastases was markedly reduced, and the tumor marker levels decreased to within the normal range. The patient subsequently underwent laparoscopic total gastrectomy with abdominal lymph node dissection, and postoperative pathological biopsy revealed a pathological complete response and R0 resection, after which the patient recovered to an excellent physical status.

CONCLUSION

To the best of our knowledge, this is the first reported case of unresectable locally advanced gastric adenocarcinoma successfully treated with quadruple therapy with a PD-1 inhibitor and chemotherapy as a first-line conversion regimen. This first-line conversion therapy with the quadruple regimen may be effective and safe for unresectable locally advanced gastric adenocarcinoma.

Key Words: Unresectable locally advanced gastric adenocarcinoma; Conversion therapy; Immunotherapy; Programmed cell death protein 1 inhibitors; Sintilimab; Case report

©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The prognosis for patients with unresectable or metastatic gastric cancer remains poor. The efficacy and safety of chemotherapy and immunotherapy require further improvement. We have designed an innovative first-line quadruple conversion therapy regimen that integrates a programmed cell death protein 1 inhibitor with chemotherapy, successfully implemented in the treatment of a patient with unresectable locally advanced gastric adenocarcinoma.

Citation: Du XY, Xia RJ, Shen LW, Ma JG, Yao WQ, Xu W, Lin ZP, Ma LB, Niu GQ, Fan RF, Xu SM, Yan L. Quadruple therapy with immunotherapy and chemotherapy as first-line conversion treatment for unresectable advanced gastric adenocarcinoma: A case report. *World J Gastrointest Oncol* 2025; 17(4): 102258

URL: https://www.wjgnet.com/1948-5204/full/v17/i4/102258.htm **DOI:** https://dx.doi.org/10.4251/wjgo.v17.i4.102258

INTRODUCTION

Gastric cancer (GC) is a significant health concern, ranking as the fifth most common cancer and the fifth leading cause of cancer-related deaths worldwide in 2022[1]. It is estimated that in 2040, there will be 1.8 million cases of GC and 1.3 million deaths, an increase of 66% and 71%, respectively, compared with 2020[2]. GC has received much attention in recent years because of its increasing global incidence. In most GC patients, the primary clinical manifestation is an intragastric mass lesion, typically in the absence of significant clinical signs. Radical surgery is primarily indicated for patients with resectable cancer lesions[3]. However, GC often remains asymptomatic in its early stages, leading to its predominant diagnosis at an advanced stage, where vascular invasion and distant metastasis have occurred. As a result, patients with advanced GC are typically ineligible for surgical intervention and face a grim prognosis.

Surgical resection remains the cornerstone of curative treatment for GC, with lymphadenectomy being pivotal to the success of radical surgery^[4]. For resectable locally advanced GC, the 2024 National Comprehensive Cancer Network and Chinese Society of Clinical Oncology (CSCO) guidelines recommend neoadjuvant chemoradiotherapy or immunotherapy prior to surgery [5]. For unresectable locally advanced or metastatic GC, conversion therapy is recommended to increase the potential for surgical resection. Systemic chemotherapy remains the cornerstone of treatment for advanced GC and is equally vital for managing unresectable locally advanced cases[6,7]. Chemotherapy regimens combining fluoropyrimidines with platinum-based drugs are recommended as the preferred first-line treatment strategy, but patient survival is typically approximately one year[8-10]. Combinations of chemotherapy drugs such as S-1 plus oxaliplatin (SOX), capecitabine plus oxaliplatin, leucovorin calcium plus fluorouracil plus oxaliplatin, and docetaxel plus oxaliplatin plus capecitabine, among others, have not overcome the efficacy limitations of chemotherapy. In recent years, immune checkpoint inhibitor (ICI)-based immunotherapy has shown significant efficacy in treating gastrointestinal malignancies. ICIs combined with chemotherapy and/or targeted therapies have demonstrated substantial benefits in both locally advanced and advanced GC[11-13]. Furthermore, compared with cisplatin, programmed cell death protein 1 (PD-1) inhibitors with oxaliplatin significantly prolong progression-free survival (PFS) in advanced GC patients[14]. On the basis of phase III clinical trial results, the Food and Drug Administration (FDA) has approved certain PD-1 inhibitors in combination with oxaliplatin and fluoropyrimidines for first-line treatment of advanced or metastatic GC, adenocarcinoma of the esophagogastric junction (AEG), and esophageal adenocarcinoma[12]. In 2022, the National Medical Products Administration (NMPA) approved the combination of sintilimab with fluoropyrimidines and platinum-based drugs as a first-line treatment for unresectable locally advanced, recurrent, or metastatic GC/gastroesophageal junction cancer (GEJC). Recent studies indicate that the combination of sintilimab with nab-paclitaxel exhibits promising antitumor activity and an acceptable safety profile as a second-line treatment for advanced or metastatic AEG/GC[15].

While a PD-1 inhibitor combined with chemotherapy can prolong the survival of unresectable advanced or metastatic GC patients, radical resection is the key approach for achieving cancer cure and long-term survival. Conversion therapy refers to unresectable or borderline resectable tumors for surgical, technical and/or oncological reasons. After active and effective chemotherapy, immunotherapy, radiotherapy and other comprehensive treatments, primary gastric lesions can be reduced to a lower stage, while metastatic lesions can be effectively controlled to achieve R0 resection and improve the long-term survival rate [16,17]. In recent years, conversion therapy has been extensively implemented in advanced hepatocellular carcinoma and colorectal cancer patients and has demonstrated significant clinical efficacy [18,19]. In 2021, data from the phase II CO-STAR trial, published by the American Society of Clinical Oncology, revealed that the combination of sintilimab, apatinib, and chemotherapy (nab-paclitaxel plus S-1) demonstrated substantial efficacy as a conversion therapy in patients with advanced GC. The trial achieved an impressive objective response rate (ORR) of 61.1%, accompanied by an R0 resection rate of 94.4% [20]. These results emphasize the potential of this therapeutic regimen to convert initially unresectable tumors into resectable tumors, significantly improving the prognosis and offering a path toward a surgical cure for advanced GC patients. Notably, approximately 80% of GC patients exhibit a human epidermal growth factor receptor 2 (HER2)-negative status, rendering them ineligible for trastuzumab-targeted therapy. In light of robust evidence from multiple phase III clinical trials, the FDA has approved the use of certain PD-1 inhibitors in combination with chemotherapy as a first-line treatment strategy for HER2-negative GC[12,21-23]. Additionally, the CSCO guidelines advocate the use of nab-paclitaxel as a first-line therapeutic option for advanced metastatic malignancies, including esophageal cancer, GEJC, and pancreatic cancer. PD-1 inhibitors, especially sintilimab, in combination with chemotherapy or targeted therapy have great potential in the treatment of advanced-stage GC patients. However, the efficacy and safety of PD-1 inhibitors, nab-paclitaxel, oxaliplatin, and S-1 in conversion therapy for HER2-negative unresectable locally advanced or advanced GC remain unclear.

Here, we report a case of unresectable locally advanced gastric adenocarcinoma treated with sintilimab in combination with nab-paclitaxel, S-1, and oxaliplatin, demonstrating the efficacy and safety of the quadruple-drug conversion therapy regimen. Encouragingly, this patient achieved a pathological complete response (pCR) and R0 resection after successful conversion therapy, with tumor marker levels returning to normal. To our knowledge, this is the first reported case of unresectable locally advanced gastric adenocarcinoma treated with this quadruple-drug conversion therapy regimen.

CASE PRESENTATION

Chief complaints

A 55-year-old male was admitted to our hospital on August 21, 2023, due to intermittent epigastric pain for 3 months, which had worsened over the past 2 months and was accompanied by melena.

History of present illness

The patient developed upper abdominal pain without obvious cause three months prior, characterized by dull distension, which typically occurred at night when hungry. The pain worsened after spicy foods were consumed and was accompanied by acid reflux and belching. Self-administered omeprazole provided minimal relief, and the symptoms recurred. Over the next two months, the symptoms intensified, with the addition of melena. Since the onset of illness, the patient maintained a stable mental state and sleep, with normal bowel and urinary functions, poor appetite, and approximately 7 kg of weight loss.

History of past illness

The patient had no history of acute or chronic infectious diseases, heart disease, hypertension, diabetes, abdominal trauma, or surgeries.

Personal and family history

The patient had no pertinent family medical history.

Physical examination

Physical examination revealed mild epigastric tenderness with no other positive signs.

Laboratory examinations

The carcinoembryonic antigen (CEA) level significantly increased to 394.12 ng/mL (normal reference range: 0-5.00 ng/mL), and the alpha-fetoprotein (AFP) level increased to 26.12 μ g/mL (normal reference range: 0-15.00 μ g/mL). The value of cancer antigen 19-9 (CA19-9) was 30.12 U/mL (normal reference range: 0-37.00 U/mL), which is near the upper limit of the normal range. Other tumor biomarkers, such as cancer antigen 125 (CA125) and cancer antigen 153, were within the normal range. The body mass index (BMI) decreased to 17.6 kg/m² (normal reference range: 18.5-23.9 kg/m²).

Du XY et al. Quadruple therapy with PD-1 inhibitor and chemotherapy

A pathological biopsy was performed on August 23, 2023, for pathological evaluation of the tumor mass. The pathological diagnosis was poorly differentiated adenocarcinoma of the gastric body (Figure 1A). On immunohistochemical evaluation, the tumor tissue was negative for Ki67, CKp, TP53, CK7, and HER2.

Imaging examinations

Enhanced abdominal computed tomography (CT) revealed irregular thickening of the gastric wall at the lesser curvature and gastric angle, with the thickest part measuring approximately 1.9 cm. The tumor infiltrated the full thickness of the gastric wall but did not involve the serosa. Multiple metastatic lymph nodes were observed in the abdominal cavity, with the largest measuring approximately 4.9 cm × 2.9 cm. Lymph node metastases were observed in the right paracardial lymph nodes, lesser curvature lymph nodes, proximal greater curvature lymph nodes, superior pyloric lymph nodes, and inferior pyloric lymph nodes surrounding the gastric cavity. Metastases were also present in the lymph nodes adjacent to the left gastric artery (perivascular) and in the lymph nodes surrounding organs, particularly those along the hepatoduodenal ligament. A total of seven groups of lymph nodes in the perigastric region exhibited metastases, with the metastatic tumors in the distal greater curvature lymph nodes being the largest in volume and most numerous. Electronic gastroscopy revealed a large ulcer on the lesser curvature of the stomach, with a foul, bleeding, and uneven base; the margins were raised, grayish in color, and rigid, accompanied by bleeding and erosion (Figure 2).

MULTIDISCIPLINARY EXPERT CONSULTATION

A comprehensive treatment strategy for unresectable, locally advanced, or advanced GC integrates pathological, radiological, and immunohistochemical assessments with the patient's clinical status, guided by current guidelines and the literature. Following a thorough evaluation by a multidisciplinary team (MDT) comprising experts in surgery, oncology, pathology, radiology, and pharmacology, factors such as pathology, clinical staging, genomics, treatment history, risk stratification, and patient preferences were analyzed. The MDT unanimously recommended first-line conversion therapy with a personalized quadruple regimen combining PD-1 inhibitors and chemotherapy to downstage the tumor and achieve R0 resection. The treatment plan, approved by the patient and family with informed consent, highlights the potential of this approach to halt tumor progression. This case highlights the importance of personalized therapy, multidisciplinary collaboration, and continuous follow-up in managing advanced GC and offers a framework applicable to other advanced cancers.

FINAL DIAGNOSIS

The patient was diagnosed with unresectable locally advanced gastric adenocarcinoma on the basis of his medical history and the imaging examination and pathology biopsy results. According to the American Joint Committee on Cancer/ Union for International Cancer Control/International Gastric Cancer Association eighth edition guidelines, the patient was diagnosed with grade cT3N3M0 gastric adenocarcinoma.

TREATMENT

Following an MDT assessment, it was determined that the patient had the following conditions: (1) Severe upper abdominal pain accompanied by melena, indicating serious clinical symptoms; (2) The presence of multiple lymph node metastases in the abdominal cavity, with significantly enlarged nodes, making surgical treatment unsuitable; (3) Poorly differentiated adenocarcinoma with high malignancy; and (4) An acceptable general condition and eagerness for a cutting-edge and effective treatment approach. Therefore, it was decided to administer the quadruple-drug regimen for first-line conversion therapy to the patient. The treatment consisted of a PD-1 inhibitor, nab-paclitaxel, S-1 and oxaliplatin. Sintilimab (200 mg iv drip, on d1), nab-paclitaxel (200 mg iv drip, on d1), S-1 (60 mg orally, twice daily, on d1-14), and oxaliplatin (180 mg iv drip, on d1) were used for 1 cycle of 21 days, for a total of 4 cycles. Imaging evaluations were conducted on the first day of the first and third cycles, as well as on the day before surgery. After nearly 4 months of treatment, enhanced abdominal CT images revealed a significant decrease in the volume of the adenocarcinoma mass of the gastric body compared with the previous scan on August 21, 2023. The maximum thickness of the tumor decreased from 1.9 cm to 0.6 cm (Figure 3A and B). The sizes and numbers of multiple lymph node metastases in the abdominal cavity also significantly decreased, with the largest measuring 1.5 cm in diameter (Figure 3A and C). The serum levels of CEA decreased significantly from 394.12 ng/mL to 2.51 ng/mL (Figure 4A), those of AFP decreased from 26.12 µg/mL to 3.64 µg/mL (Figure 4B), and those of CA19-9 decreased from 30.10 U/mL to 2.60 U/mL (Figure 4C), with all tumor marker levels within the normal range. The BMI increased from 17.6 (weight: 51.0 kg, height: 1.70 m) to 19.0 (weight: 55.0 kg, height: 1.70 m kg/m². After 4 cycles of conversion therapy, the patient's abdominal pain and melena resolved, with a significant reduction in the size and volume of the primary tumor, as well as a marked decrease in the size and number of lymph node metastases, and the patient's overall condition remained good. Following discussions with the treatment team and with agreement from the patient and family members, the patient underwent laparoscopic total gastrectomy with abdominal lymph node dissection on December 19, 2023, achieving R0 resection. The postoperative pathological findings revealed fibrosis and calcification at the tumor bed of the gastric body, along with fibrosis and calcification in





Figure 1 Hematoxylin-eosin staining and immunohistochemical evaluation of the obtained using a pathological biopsy. A: The preoperative pathology image showed poorly differentiated adenocarcinoma of the gastric body; B: The specimen of the entire stomach, lymph node and tumor tissue removed during surgery; C: The postoperative pathology image showed no residual tumor cells.



Figure 2 Endoscopic images.

some of the dissected lymph nodes, with no residual cancerous tissue observed (Figure 1B and C). The tumor demonstrated complete regression [tumor regression grade (TRG) 0] with a pathological stage of pT0N0M0, indicating pCR and R0 resection. Postoperatively, the patient received sintilimab and SOX adjuvant therapy according to the treatment protocol. Sintilimab (200 mg iv drip, on d1), S-1 (60 mg orally, twice daily, on d1-14), and oxaliplatin (180 mg iv drip, on d1) were used for 1 cycle of 21 days, for a total of 2 cycles. The patient recovered well during the 6.5-month follow-up period. He had a PFS of more than 3.6 months and an overall survival of more than 6.5 months after receiving combination therapy. The timeline of treatment is shown in Figure 4D.



Figure 3 Enhanced abdominal computed tomography images for evaluating the treatment response. A: Upper-row images show the changes in the size of the adenocarcinoma tumor tissue at the gastric body; Lower-row images show the changes in the size of the lymph node metastasis in the abdominal cavity; B: The maximum thickness of the tumor at the gastric body; C: The maximum diameter of the lymph node metastatic tumor.

Adverse events (AEs) were observed during first-line conversion therapy. The main AEs included neutropenia, leukopenia, thrombocytopenia, moderate anemia, fatigue, nausea, and decreased appetite. During the quadruple therapy, neutropenia occurred 4 times, with the lowest value of 0.54×10^{9} /L (grade 3 AE), which returned to normal levels after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) injections; leukopenia occurred 3 times, with the lowest value of 1.22×10^{9} /L (grade 3 AE), which returned to normal levels after rhGM-CSF injections; thrombocytopenia occurred 1 time, with the lowest value of 36×10^{9} /L (grade 3 AE), which returned to normal levels after recombinant human thrombopoietin injections and interleukin-11 injections; hemoglobin decreased once, with the lowest value of 88 g/L (grade 2 AE), which returned to normal levels after compound ferrous sulfate folic acid tablets, vitamin B12, and vitamin B6; and mild fatigue, nausea, and decreased appetite were observed but were left untreated, resolving on their own. No immune-related AEs occurred. During conversion therapy, the patient experienced grade 2-3 hematologic AEs, likely due to chemotherapy-induced myelosuppression. These issues were resolved with symptomatic treatment, enabling uninterrupted completion of therapy.

OUTCOME AND FOLLOW-UP

This patient was miserable when he was diagnosed with unresectable locally advanced gastric adenocarcinoma. He consented to the treatment scheme. After receiving conversion therapy, the patient noticed rapid improvement in his condition. In the treatment process, first-line conversion therapy with a quadruple regimen eradicated the patient's clinical symptoms, downstaged the tumor, and led to complete tumor regression (TRG 0), pCR, and R0 resection. No grade 4 or higher AEs occurred. The patient was relieved upon being informed that no tumor cells remained and that his serum CA125 and AFP levels were within the normal range. The patient recovered well during the 6.5-month follow-up period. He had a PFS of more than 3.6 months and an OS of more than 6.5 months after receiving combination therapy.

Du XY et al. Quadruple therapy with PD-1 inhibitor and chemotherapy



Figure 4 Dynamics of carcinoembryonic antigen, alpha-fetoprotein, and cancer antigen 19-9 and timeline of treatment options. A-C: Diagram depicting the dynamic of carcinoembryonic antigen (A), alpha-fetoprotein (B) and cancer antigen 19-9 (C); D: The timeline of the treatment protocol. CEA: Carcinoembryonic antigen; AFP: Alpha-fetoprotein; CA19-9: Cancer antigen 19-9; IHC: Immunohistochemistry; CT: Computed tomography; AEs: Adverse events; GC: Gastric cancer; PR: Partial response; BMI: Body mass index; pCR: Pathological complete response; PFS: Progression-free survival; OS: Overall survival.

The patient and family members were satisfied with the efficacy and safety of this treatment approach. He gladly agreed to reveal his case.

DISCUSSION

The quadruple combination therapy of PD-1 inhibitors with nab-paclitaxel, S-1, and oxaliplatin represents a promising approach as a first-line conversion therapy for unresectable locally advanced gastric adenocarcinoma. This therapeutic strategy is designed to leverage the synergistic effects of immunotherapy and chemotherapy to maximize tumor reduction and potentially enable R0 resection and pCR.

A substantial proportion of GCs are diagnosed at advanced stages, precluding surgical intervention. Before 2021, systemic chemotherapy was the standard treatment for unresectable or metastatic GC, but modifications in regimens yielded limited improvements in OS. Recently, immunotherapy has emerged as a transformative approach. Pivotal phase III trials, including ORIENT-16, CheckMate-649, and KEYNOTE-590, have demonstrated that adding PD-1 inhibitors to chemotherapy as first-line treatment significantly improves survival in advanced or metastatic AEG and GC patients

compared with chemotherapy alone[11,12,24]. On the basis of these findings, the FDA approved PD-1 inhibitors combined with chemotherapy in 2021 as first-line treatments for advanced AEG and GC, marking a major milestone in immunotherapy. In 2022, the NMPA approved sintilimab with fluoropyrimidine and platinum-based chemotherapy for unresectable locally advanced, recurrent, or metastatic AEG and GC, further highlighting its efficacy. These approaches establish PD-1 inhibitors, particularly sintilimab, combined with chemotherapy as the standard first-line treatment for advanced GC, offering significant survival benefits.

Advanced GC is associated with a poor prognosis, with a 5-year survival rate of approximately 10%[25]. Despite advancements in immunotherapy, targeted therapies, oncolytic viruses, and cancer vaccines, advanced GC remains largely incurable and presents significant therapeutic challenges. Recent studies suggest that conversion therapy offers a potential pathway to cure this disease, providing new hope in this context. However, no consensus exists on optimal regimens, and evidence is limited to retrospective analyses and phase II trials, with a lack of phase III studies specifically on conversion therapy for GC. Retrospective studies have reported R0 resection rates of 56.4%-84.8% after conversion surgery and a median OS of 22.5-50.0 months [26-31]. Dual and triplet chemotherapy regimens are commonly used, with triplet regimens offering slightly better efficacy but limited by toxicity and poor tolerance. The median OS remains at 1-2 years. Although promising, conversion immunotherapy is understudied, with limited clinical data. Two retrospective studies revealed that combining PD-1 inhibitors (e.g., sintilimab) with dual chemotherapy or targeted therapies improved the conversion and R0 resection rates, prolonging postoperative survival [32,33]. The CO-STAR phase II trial evaluated sintilimab and apatinib with dual chemotherapy for stage IV metastatic GC. The results revealed an ORR of 61.7%, an R0 conversion rate of 59.6%, and a high R0 resection rate of 94.4% among those who underwent surgery. Additionally, an ongoing phase III trial (NCT05002686) is assessing sintilimab with nab-paclitaxel, oxaliplatin, capecitabine, and radiotherapy as a first-line treatment for advanced GC with retroperitoneal lymph node metastasis, followed by D2 gastrectomy[34]. In summary, conversion therapy, particularly PD-1 inhibitors such as sintilimab combined with chemotherapy or targeted agents, shows promise in improving conversion rates and achieving R0 resections in advanced GC. However, further studies are needed to validate its safety and efficacy.

Conventional chemotherapy has shown limited efficacy in the treatment of advanced or metastatic GC. Meta-analyses suggest that ICIs as monotherapies may increase the risk of early mortality[35]. However, combining ICIs with chemotherapy significantly improves OS and PFS[36]. Sintilimab, a PD-1-targeted antibody, achieves remarkable efficacy in advanced GC by blocking the PD-1/PD-L1 pathway [24,37-39]. Nab-paclitaxel addresses the limitations of traditional paclitaxel, significantly enhances efficacy and reduces toxicity, and is widely used in advanced GC treatment[40,41]. Studies have demonstrated that the combination of nab-paclitaxel with S-1 produces superior outcomes[42], markedly increasing R0 resection rates in the neoadjuvant setting[43]. Retrospective studies reported a pCR rate of 21.52% with the combination of camrelizumab, S-1, and nab-paclitaxel, surpassing SOX and SAP (S-1 plus nab-paclitaxel) regimens[44]. The CO-STAR study further revealed that sintilimab combined with nab-paclitaxel, S-1, and apatinib achieved an R0 resection rate of 94.4% and an ORR of 61.7% [20]. These findings highlight the potential of the quadruple regimen, comprising sintilimab, nab-paclitaxel, oxaliplatin, and S-1, to synergistically enhance efficacy, reduce resistance, and optimize outcomes. Previously, our team employed a triple regimen of sintilimab, S-1, and oxaliplatin for conversion therapy in advanced unresectable GC, but the results were suboptimal. To improve efficacy, nab-paclitaxel was introduced into the regimen. Owing to its demonstrated efficacy and manageable toxicity in studies such as CO-STAR, this quadruple regimen holds great promise. Conversion therapy aims to downstage unresectable or borderline-resectable tumors to facilitate R0 resection, thereby improving long-term survival. Our patient presented with extensive lymph node metastases and large metastatic lesions, precluding surgical intervention. Following MDT evaluation, the patient underwent the quadruple regimen. Postoperative pathology revealed a pCR, with a final stage of T0N0M0. The patient recovered well. For adjuvant therapy, we considered sintilimab combined with SOX or SOX monotherapy at the same dose. Studies have shown that sintilimab combined with SOX achieves higher pCR rates and better major pathological responses than does SOX alone in the perioperative treatment of advanced GC[45]. Additionally, sintilimab combined with chemotherapy has demonstrated superior PFS and OS in HER2-negative advanced GC patients[46]. On the basis of the patient's excellent response and supporting evidence, two cycles of sintilimab combined with SOX were administered as adjuvant therapy. In summary, the quadruple regimen integrates the complementary mechanisms of immunotherapy and chemotherapy, significantly enhancing efficacy, reducing resistance, and minimizing chemotherapy-related toxicity. This approach improves patient outcomes and quality of life. Although challenges such as drug interactions, potential side effects, individual variability, and treatment costs exist, these can be effectively managed through rational therapeutic strategies. The success of this regimen further validates its potential as a first-line treatment for advanced GC. Continued research and clinical optimization are expected to expand its applicability and therapeutic value across diverse clinical settings

Owing to its personalized and experimental nature, this regimen has not yet been incorporated into clinical guidelines. Large-scale studies are still needed to definitively establish its efficacy, safety, and appropriate indications. The treatment team recommends that candidates for the quadruple regimen fulfill the following criteria: (1) Patients with unresectable, locally advanced, recurrent, or metastatic HER2-negative GC; (2) Those who experience clinical symptoms that significantly impair their quality of life; and (3) Patients who are relatively young, in good overall health, without major comorbidities or underlying conditions, and are expected to tolerate potential adverse reactions well. The severity of adverse reactions plays a crucial role in determining the overall effectiveness of treatment and patient adherence. In the sole reported study on conversion therapy for advanced GC using a four-drug regimen combining immunotherapy and chemotherapy, the most commonly observed adverse reactions with sintilimab, oxaliplatin, S-1, and apatinib were grade 2-3, indicating that the toxicity of the sintilimab-based quadruple regimen remained tolerable. During the treatment of this patient, the observed AEs included neutropenia, leukopenia, thrombocytopenia, moderate anemia, fatigue, nausea, and loss of appetite, all of which were classified as grade 3 or lower. These effects are relatively mild and are likely



attributed to postchemotherapy bone marrow suppression. The patient successfully completed the treatment cycle on schedule, exhibiting excellent adherence and tolerance, further underscoring the favorable safety profile of the quadruple regimen comprising sintilimab, nab-paclitaxel, oxaliplatin, and S-1 as a first-line conversion therapy for unresectable, locally advanced gastric adenocarcinoma. Although the quadruple regimen demonstrated a favorable safety profile in this case, ensuring its broader safety across a larger patient population necessitates personalized treatment approaches, continuous monitoring, multidisciplinary collaboration, and proactive strategies for the prevention and management of AEs. To mitigate and manage adverse reactions, the treatment team recommends the following: (1) Pretreatment assessment: Comprehensive evaluation of health, medical history, organ function, and risk factors to guide personalized treatment and identify high-risk patients; (2) Dynamic monitoring: Regular checks of blood counts, liver/kidney function, electrolytes, heart, and thyroid function to detect early signs of adverse reactions, with a focus on hematologic and hepatotoxicity during immunotherapy and chemotherapy; and (3) Management of AEs: IrAEs: These include skin, gastrointestinal, hepatic toxicity, or immune-mediated thyroid disorders. Grade 1 irAEs are managed with supportive care; Grade 2 irAEs require pausing immunotherapy and administering corticosteroids or immunosuppressants; and Grade 3-4 irAEs necessitate the immediate discontinuation of immunotherapy, administration of high-dose immunosuppressants, and hospitalization for monitoring. Chemotherapy-related AEs: These include hematologic, neurotoxic, and renal toxicities. Grade 1 AEs are managed symptomatically; Grade 2 AEs involve dose adjustments and enhanced monitoring; Grade 3 AEs require pausing or adjusting chemotherapy and hospitalization for observation; and Grade 4 AEs require immediate cessation of chemotherapy and urgent hospitalization for life support. To balance efficacy and toxicity, the treatment team recommends the following: (1) Individual variations: Personalized treatment is crucial because of differences in immune response and drug metabolism. Healthy, young patients tolerate combination therapies better, whereas those with comorbidities may require dose adjustments; (2) Treatment adjustments: Early detection and monitoring help balance efficacy and toxicity, optimize outcomes and minimize harm; (3) Patient education and adherence: Enhancing patients' understanding of side effects improves adherence and treatment success; and (4) Prospective research: Large-scale trials will further assess the efficacy-toxicity balance of combination therapies, providing solid evidence for treatment optimization and clinical decision-making. During the patient's treatment, although most adverse reactions were chemotherapy-related events of grades 2-3, we successfully reduced them to Grades 0-1 through timely monitoring and symptomatic treatment. This ensured the smooth execution of the treatment plan and achieved the desired therapeutic outcomes. This process not only reflects the clinical expertise of our team but is also supported by studies such as CO-STAR, providing valuable insights into the diagnosis and treatment of gastric and other cancers.

A comprehensive treatment strategy for unresectable, locally advanced, or advanced GC integrates pathological, radiological, and immunohistochemical assessments with the patient's clinical status, guided by current guidelines and the literature. Following a thorough evaluation by an MDT comprising experts in surgery, oncology, pathology, radiology, and pharmacology, factors such as pathology, clinical staging, genomics, treatment history, risk stratification, and patient preferences were analyzed. The MDT unanimously recommended first-line conversion therapy with a personalized quadruple regimen combining PD-1 inhibitors and chemotherapy to downstage the tumor and achieve R0 resection. The treatment plan, approved by the patient and family with informed consent, highlights the potential of this approach to halt tumor progression. This case highlights the importance of personalized therapy, multidisciplinary collaboration, and continuous follow-up in managing advanced GC and offers a framework applicable to other advanced cancers.

CONCLUSION

To the best of our knowledge, this is the first reported case of first-line conversion therapy in an unresectable locally advanced gastric adenocarcinoma patient utilizing PD-1 inhibitors in combination with nab-paclitaxel, S-1, and oxaliplatin. The patient was downstaged to pT0N0M0, achieving pCR and R0 resection, with a PFS of more than 3.6 months, an OS of more than 6.5 months, and no grade 4 or higher AEs. After 6.5 months of treatment, the patient achieved excellent physical status. The accumulation of cases and evidence from prospective studies involving locally advanced GC, especially unresectable or advanced GC, are needed to validate the safety and efficacy of this quadruple therapy in conversion therapy. Based on the current preliminary results, the combination of PD-1 inhibitors, nab-paclitaxel, S-1, and oxaliplatin demonstrates considerable potential in the treatment of locally advanced GC. With further clinical research and validation, this therapeutic regimen could become a more effective and safer treatment option for patients with GC and other gastrointestinal malignancies in the future.

ACKNOWLEDGEMENTS

We acknowledge the patient and her family for allowing us to publish the report. We also thank our colleagues for their work on the treatment course.

Raisbideng® WJGO https://www.wjgnet.com

FOOTNOTES

Author contributions: Du XY, Xia RJ and Shen LW contributed equally to this work; Xu SM and Yan L contributed equally to this work as co-corresponding authors; Du XY was responsible for drafting of the manuscript; Xu SM and Yan L were responsible for planning treatment decisions; Xia RJ, Shen LW and Ma JG were responsible for evaluating imaging outcome; Du XY and Xia RJ were listed as cofirst authors; Yao WQ and Xu W were responsible for pathological interpretation; Du XY, Xia RJ, Shen LW, Ma JG, Xu W, Lin ZP, Ma LB, Niu GQ, Fan RF, Xu SM and Yan L were responsible for clinical data analysis and taking care of the patient; all authors contributed to the article and approved the submitted version.

Supported by the Health Industry Research Program of Gansu Province, No. GSWSKY2021-043; the Youth Science and Technology Foundation of Gansu Province, No. 22JR11RA002; and the Natural Science Foundation of Gansu Province, No. 22JR5RA008.

Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country of origin: China

ORCID number: Long Yan 0009-0004-0029-3402.

S-Editor: Lin C L-Editor: A P-Editor: Zhao YQ

REFERENCES

- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of 1 incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229-263 [PMID: 38572751 DOI: 10.3322/caac.21834]
- Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, Meheus F, Verhoeven RHA, Vignat J, Laversanne M, Ferlay J, 2 Soerjomataram I. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study. EClinicalMedicine 2022; 47: 101404 [PMID: 35497064 DOI: 10.1016/j.eclinm.2022.101404]
- Lin F, Chen Y, Huang B, Ruan S, Lin J, Chen Z, Huang C, Zhao B. Application of immune checkpoint inhibitors for resectable gastric/ 3 gastroesophageal cancer. Front Pharmacol 2024; 15: 1391562 [PMID: 38783944 DOI: 10.3389/fphar.2024.1391562]
- Li GZ, Doherty GM, Wang J. Surgical Management of Gastric Cancer: A Review. JAMA Surg 2022; 157: 446-454 [PMID: 35319717 DOI: 4 10.1001/jamasurg.2022.0182]
- 5 National Comprehensive Cancer Network. NCCN Guidelines Version 5.2024 - Gastric Cancer. [cited 11 February 11 2024]. Available from: https://www.nccn.org/home
- Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, 6 Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20: 167-192 [PMID: 35130500 DOI: 10.6004/jnccn.2022.0008]
- Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 2021; 24: 1-21 7 [PMID: 32060757 DOI: 10.1007/s10120-020-01042-y]
- Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, 8 Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221 [PMID: 18282805 DOI: 10.1016/S1470-2045(08)70035-4]
- 9 Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol 2015; 26: 141-148 [PMID: 25316259 DOI: 10.1093/annonc/mdu472]
- Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, 10 Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
- Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong 11 P, Maqueda MA, Goekkurt E, Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P, Kato K; KEYNOTE-590



Investigators. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021; 398: 759-771 [PMID: 34454674 DOI: 10.1016/S0140-6736(21)01234-4

- 12 Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021; 398: 27-40 [PMID: 34102137 DOI: 10.1016/S0140-6736(21)00797-2]
- 13 Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Cil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24: 1181-1195 [PMID: 37875143 DOI: 10.1016/S1470-2045(23)00515-6]
- Guo X, Yang B, He L, Sun Y, Song Y, Qu X. PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for 14 advanced gastric cancer: A network meta-analysis. Front Immunol 2022; 13: 905651 [PMID: 36003374 DOI: 10.3389/fimmu.2022.905651]
- Wang J, He Y, Zhang B, Lv H, Nie C, Chen B, Xu W, Zhao J, Cheng X, Li Q, Tu S, Chen X. The Efficacy and Safety of Sintilimab Combined 15 With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer. Front Oncol 2022; 12: 924149 [PMID: 35719979 DOI: 10.3389/fonc.2022.924149]
- Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L. Resection of nonresectable liver metastases from 16 colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-20; discussion 520 [PMID: 8857855 DOI: 10.1097/00000658-199610000-00009]
- 17 Yang H, Ji K, Ji J. Current status and perspectives of conversion therapy for advanced gastric cancer. Chin J Cancer Res 2022; 34: 109-114 [PMID: 35685991 DOI: 10.21147/j.issn.1000-9604.2022.02.05]
- Zhang W, Tong S, Hu B, Wan T, Tang H, Zhao F, Jiao T, Li J, Zhang Z, Cai J, Ye H, Wang Z, Chen S, Wang Y, Li X, Wang F, Cao J, Tian L, 18 Zhao X, Chen M, Wang H, Cai S, Hu M, Bai Y, Lu S. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial. J Immunother Cancer 2023; 11 [PMID: 37730273 DOI: 10.1136/jitc-2023-007366]
- Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients 19 With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis. JAMA Oncol 2017; 3: e170278 [PMID: 28542671 DOI: 10.1001/jamaoncol.2017.0278]
- Xue Q, Wang B, Wang X, Ding X, Liu Y, Wang X, Liu N, Zhan H, Ke B, Li B, Cai M, Deng J, Wu L, Huang W, Liu H, Sun Y, Liang H. CO-20 STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with Nab-PTX, S-1 and apatinib for the first-line treatment of stage IV gastric cancer (GC). J Clin Oncol 2021; 39: e16041-e16041 [DOI: 10.1200/jco.2021.39.15_suppl.e16041]
- 21 Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol 2020; 6: 1571-1580 [PMID: 32880601 DOI: 10.1001/jamaoncol.2020.3370]
- Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, 22 Azuma M, Chen LT, Kang YK. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol 2019; 30: 250-258 [PMID: 30566590 DOI: 10.1093/annonc/mdy540]
- Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, 23 Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022; 23: 234-247 [PMID: 35030335 DOI: 10.1016/S1470-2045(21)00692-6]
- Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H, Luo S, Qin Y, Guo Q, Bai Y, Ling Y, Yang J, Yan Z, Yang L, Tang 24 Y, He Y, Zhang L, Liang X, Niu Z, Zhang J, Mao Y, Guo Y, Peng B, Li Z, Liu Y, Wang Y, Zhou H; ORIENT-16 Investigators. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial. JAMA 2023; 330: 2064-2074 [PMID: 38051328 DOI: 10.1001/jama.2023.19918]
- 25 Alsina M, Arrazubi V, Diez M, Tabernero J. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol 2023; 20: 155-170 [PMID: 36344677 DOI: 10.1038/s41575-022-00703-w]
- Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Shinya M, Katsuki S, Takahashi M, Maeda M, Okagawa 26 Y, Naoki U, Kikuch S, Okamoto K, Miyamoto H, Shimada M, Takemasa I, Kato J, Takayama T. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer 2017; 20: 517-526 [PMID: 27553665 DOI: 10.1007/s10120-016-0633-1]
- Beom SH, Choi YY, Baek SE, Li SX, Lim JS, Son T, Kim HI, Cheong JH, Hyung WJ, Choi SH, Jung M, Kim HS, Jeung HC, Chung HC, Rha 27 SY, Noh SH. Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. BMC Cancer 2018; 18: 1116 [PMID: 30442107 DOI: 10.1186/s12885-018-4998-x]
- Sym SJ, Chang HM, Ryu MH, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK. Neoadjuvant docetaxel, capecitabine and cisplatin 28 (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. Ann Surg Oncol 2010; 17: 1024-1032 [PMID: 19941081 DOI: 10.1245/s10434-009-0838-1]
- 29 Morgagni P, Solaini L, Framarini M, Vittimberga G, Gardini A, Tringali D, Valgiusti M, Monti M, Ercolani G. Conversion surgery for gastric cancer: A cohort study from a western center. Int J Surg 2018; 53: 360-365 [PMID: 29654967 DOI: 10.1016/j.ijsu.2018.04.016]
- Yabusaki H, Nashimoto A, Matsuki A, Aizawa M. Significance of surgical treatment in multimodal therapy for stage IV highly advanced 30 gastric cancer. Hepatogastroenterology 2013; 60: 377-381 [PMID: 22975650 DOI: 10.5754/hge12653]
- Kinoshita J, Fushida S, Tsukada T, Oyama K, Okamoto K, Makino I, Nakamura K, Miyashita T, Tajima H, Takamura H, Ninomiya I, Ohta T. 31 Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer. Eur J Surg Oncol 2015; 41: 1354-1360 [PMID: 26028256 DOI: 10.1016/j.ejso.2015.04.021]



- Xiang X, Guo F, Li G, Ma L, Zhu X, Abdulla Z, Li J, Zhang J, Huang M. Efficacy of intra-arterial chemotherapy with sequential anti-PD-1 32 antibody in unresectable gastric cancer: A retrospective real-world study. Front Oncol 2022; 12: 1015962 [PMID: 36686751 DOI: 10.3389/fonc.2022.1015962
- Liang H, Yan X, Li Z, Chen X, Qiu Y, Li F, Wang M, Huang Z, Huang K, Xie Q, Zhang H, Zhong R, Zhao Z, Zou Y, Yu J, Hu Y, Liu H, Li 33 G, Zhao L. Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancer. Int J *Surg* 2023; **109**: 4162-4172 [PMID: 37720943 DOI: 10.1097/JS9.000000000000738]
- Li C. Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With 34 Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis. [accessed 2021 Aug 24]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: http://clinicaltrials.gov/show/NCT05002686 ClinicalTrials.gov Identifier: NCTNCT05002686
- 35 Viscardi G, Tralongo AC, Massari F, Lambertini M, Mollica V, Rizzo A, Comito F, Di Liello R, Alfieri S, Imbimbo M, Della Corte CM, Morgillo F, Simeon V, Lo Russo G, Proto C, Prelaj A, De Toma A, Galli G, Signorelli D, Ciardiello F, Remon J, Chaput N, Besse B, de Braud F, Garassino MC, Torri V, Cinquini M, Ferrara R. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. Eur J Cancer 2022; 177: 175-185 [PMID: 36368251 DOI: 10.1016/j.ejca.2022.09.031]
- Noori M, Mahjoubfar A, Azizi S, Fayyaz F, Rezaei N. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-36 line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis. Int Immunopharmacol 2022; 113: 109317 [PMID: 36252494 DOI: 10.1016/j.intimp.2022.109317]
- 37 Ding P, Guo H, Sun C, Yang P, Kim NH, Tian Y, Liu Y, Liu P, Li Y, Zhao Q. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study. BMC Gastroenterol 2022; 22: 121 [PMID: 35287591 DOI: 10.1186/s12876-022-02199-9]
- Mei Y, Shi M, Zhu Z, Yuan H, Yan C, Li C, Feng T, Yan M, Zhang J, Zhu Z. Addition of sintilimab to nanoparticle albumin-bound paclitaxel 38 and S-1 as adjuvant therapy in stage IIIC gastric cancer. Future Oncol 2022; 18: 139-148 [PMID: 34877867 DOI: 10.2217/fon-2021-1020]
- Wang J, Fei K, Jing H, Wu Z, Wu W, Zhou S, Ni H, Chen B, Xiong Y, Liu Y, Peng B, Yu D, Jiang H, Liu J. Durable blockade of PD-1 39 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs 2019; 11: 1443-1451 [PMID: 31402780 DOI: 10.1080/19420862.2019.1654303]
- Nakayama N, Ishido K, Chin K, Nishimura K, Azuma M, Matsusaka S, Inokuchi Y, Tanabe S, Kumekawa Y, Koizumi W. A phase I study of 40 S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer. Gastric Cancer 2017; 20: 350-357 [PMID: 27189323 DOI: 10.1007/s10120-016-0614-4]
- Ahmad S, Lambuk L, Ahmed N, Mussa A, Tee V, Mohd Idris RA, Sahran NF, Chan YY, Hassan R, Lee YY, Mohamud R. Efficacy and safety 41 of nab-paclitaxel in metastatic gastric cancer: a meta-analysis. Nanomedicine (Lond) 2023; 18: 1733-1744 [PMID: 37982749 DOI: 10.2217/nnm-2022-0300]
- He MM, Wang F, Jin Y, Yuan SO, Ren C, Luo HY, Wang ZO, Qiu MZ, Wang ZX, Zeng ZL, Li YH, Wang FH, Zhang DS, Xu RH. Phase II 42 clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer. Cancer Sci 2018; 109: 3575-3582 [PMID: 30281875 DOI: 10.1111/cas.13813]
- Watson S, de la Fouchardière C, Kim S, Cohen R, Bachet JB, Tournigand C, Ferraz JM, Lefevre M, Colin D, Svrcek M, Meurisse A, Louvet 43 C. Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST). Eur J Cancer 2019; 107: 46-52 [PMID: 30529902 DOI: 10.1016/j.ejca.2018.11.006]
- Lin JL, Lin JX, Lin JP, Zheng CH, Li P, Xie JW, Wang JB, Lu J, Chen QY, Huang CM. Safety and Efficacy of Camrelizumab in Combination 44 With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion. Front Immunol 2021; 12: 783243 [PMID: 35116023] DOI: 10.3389/fimmu.2021.783243]
- Huang X, Fang J, Huang L, Chen H, Chen H, Chai T, Ye Z, Chen H, Xu Q, Du Y, Yu P. SOX combined with sintilimab versus SOX alone in 45 the perioperative management of locally advanced gastric cancer: a propensity score-matched analysis. Gastric Cancer 2023; 26: 1040-1050 [PMID: 37768447 DOI: 10.1007/s10120-023-01431-z]
- Cai T, Liang L, Zhao X, Lin C, Li D, Zheng J. Comparative efficacy and tolerability of first-line treatments for untreated, HER2-negative, 46 advanced gastric cancer: systematic review and network meta-analysis. Crit Rev Oncol Hematol 2024; 193: 104216 [PMID: 38029945 DOI: 10.1016/j.critrevonc.2023.104216]



WJGO | https://www.wjgnet.com



Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

